Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ: HROW )

23.01 +0.77 (+3.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
From Harrow, Inc.
Via Business Wire
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
From Harrow, Inc.
Via Business Wire
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
From Harrow, Inc.
Via Business Wire
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
From Harrow, Inc.
Via Business Wire
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces Participation in Upcoming Investor Conferences
From Harrow, Inc.
Via Business Wire
Harrow Announces Third Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
From Harrow, Inc.
Via Business Wire
Harrow Announces Market Access Wins for VEVYE®
From Harrow, Inc.
Via Business Wire
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
From Harrow, Inc.
Via Business Wire
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
From Harrow, Inc.
Via Business Wire
Harrow Provides TRIESENCE® Relaunch Update
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
From Harrow, Inc.
Via Business Wire
3 Stocks Insiders are Buying That Should be on Your Radar
Unusual insider activity indicates opportunities in these stocks positioned to deliver value for shareholders this year. 
Via MarketBeat
Harrow to Present at Two Investor Conferences in May
From Harrow, Inc.
Via Business Wire
Harrow Announces First Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
From Harrow, Inc.
Via Business Wire
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
From Harrow, Inc.
Via Business Wire
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
From Harrow, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.